Table 2. Phenotypic Analysis of... | American Society of Hematology

Table 2.

Phenotypic Analysis of Myeloid/NK Cell Precursor Acute Leukemia Cases

	Case No.
	1	2	3	4	5^*	6	7
	LN	PB	BM	BM	BM	BM	BM
CD1	10	1	1	0	0	0	1
CD2	17	7	28	6	6	9	7
CD3	13	5	4	5	5	4	5
CD4	12	5	2	3	2	3	19
CD5	14	6	13	9	19	6	23
CD6	44	12	8	60	6	24	29
CD7	89	94	96	89	94	84	64
CD8	5	7	4	2	3	4	4
CD9	90	87	21	42	26	10	37
CD10	1	1	1	0	0	4	3
CD11a	ND	34	98	91	55	78	74
CD11b	72	82	56	24	88	74	85
CD11c	ND	26	40	10	4	27	37
CD13	19	4	5	65	0	13	21
CD14	5	3	1	0	0	3	17
CD15	10	5	2	5	1	10	22
CD16	1	5	0	1	1	2	8
CD19	2	11	3	1	0	8	9
CD20	2	3	3	2	0	6	2
CD21	1	2	2	1	1	1	2
CD25	4	7	1	1	0	2	26
CD28	8	3	25	4	3	4	3
CD33	80	49	76	43	74	63	92
CD34	74	67	30	60	78	50	43
CD36	3	4	9	3	4	6	17
CD38	42	81	96	81	93	88	94
CD41b	4	3	3	0	1	3	1
CD56	78	86	77	77	46	41	66
CD57	1	3	3	2	3	1	2
CD71	64	88	66	89	64	36	59
CD122	ND	2	2	1	1	3	28
HLA-DR	86	86	61	92	9	19	66
TCRαβ	14	4	2	4	4	3	5
TCRγδ	ND	1	2	0	1	ND	1
cyCD3	ND	18^†	12^†	5	4	15^†	6
cyCD22	ND	3	1	1	ND	3	0
cyCD33	ND	12	37	41	22	70	57
cyIgM	ND	ND	10	2	ND	ND	4
cyMPO	ND	35	65	28	19	1	82
TdT	ND	2	1	2	12	4	5

	Case No.
	1	2	3	4	5^*	6	7
	LN	PB	BM	BM	BM	BM	BM
CD1	10	1	1	0	0	0	1
CD2	17	7	28	6	6	9	7
CD3	13	5	4	5	5	4	5
CD4	12	5	2	3	2	3	19
CD5	14	6	13	9	19	6	23
CD6	44	12	8	60	6	24	29
CD7	89	94	96	89	94	84	64
CD8	5	7	4	2	3	4	4
CD9	90	87	21	42	26	10	37
CD10	1	1	1	0	0	4	3
CD11a	ND	34	98	91	55	78	74
CD11b	72	82	56	24	88	74	85
CD11c	ND	26	40	10	4	27	37
CD13	19	4	5	65	0	13	21
CD14	5	3	1	0	0	3	17
CD15	10	5	2	5	1	10	22
CD16	1	5	0	1	1	2	8
CD19	2	11	3	1	0	8	9
CD20	2	3	3	2	0	6	2
CD21	1	2	2	1	1	1	2
CD25	4	7	1	1	0	2	26
CD28	8	3	25	4	3	4	3
CD33	80	49	76	43	74	63	92
CD34	74	67	30	60	78	50	43
CD36	3	4	9	3	4	6	17
CD38	42	81	96	81	93	88	94
CD41b	4	3	3	0	1	3	1
CD56	78	86	77	77	46	41	66
CD57	1	3	3	2	3	1	2
CD71	64	88	66	89	64	36	59
CD122	ND	2	2	1	1	3	28
HLA-DR	86	86	61	92	9	19	66
TCRαβ	14	4	2	4	4	3	5
TCRγδ	ND	1	2	0	1	ND	1
cyCD3	ND	18^†	12^†	5	4	15^†	6
cyCD22	ND	3	1	1	ND	3	0
cyCD33	ND	12	37	41	22	70	57
cyIgM	ND	ND	10	2	ND	ND	4
cyMPO	ND	35	65	28	19	1	82
TdT	ND	2	1	2	12	4	5

Values are expressed as percentages of cells positive for each marker. Leukemic cells considered to be positive for each marker are underlined.

Abbreviation: ND, not determined.

Patient no. 5 was immunophenotyped at the time of relapse.

Dimly positive, as described in Fig 3.